Senseonics Holdings Inc SENS

Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.
20451 Seneca Meadows Parkway
Germantown, MD 20876
United States
301-515-7260

http://www.senseonics.com
https://www.eversensediabetes.com/

What makes Eversense® different?

Engineered for long-lasting accuracy and ease of use, the Eversense Long-Term Continuous Glucose Monitoring (CGM) System offers advantages over traditional CGM.

No weekly sensor self-insertions: With Eversense, a trained physician numbs the area and places the sensor in the upper arm and you’re good to go for up to 3-months.

Quickly detects glucose highs and lows: In clinical studies, the Eversense system detected 95% of hypoglycemic episodes (70 mg/dL) and 99% of hyperglycemic episodes (180 mg/dL) within 15 minutes.1

Alerts you can see, feel and hear: The Eversense CGM System can be configured to provide three types of alerts: visual, auditory, and on-body vibe alerts, which can provide you with an additional safety advantage, even during sleep.

Discreet and flexible: The smart transmitter, with its low profile and flexibility to remove and reattach without wasting a sensor, enables a new level of discretion.